Aufman Associates Inc Buys 2,299 Shares of Moderna, Inc. (NASDAQ:MRNA)

Aufman Associates Inc grew its stake in Moderna, Inc. (NASDAQ:MRNA) by 26.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,066 shares of the company’s stock after purchasing an additional 2,299 shares during the period. Aufman Associates Inc’s holdings in Moderna were worth $460,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Wilmington Savings Fund Society FSB grew its holdings in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after purchasing an additional 587 shares during the last quarter. Compass Planning Associates Inc purchased a new position in shares of Moderna during the fourth quarter valued at approximately $37,000. Venturi Wealth Management LLC grew its stake in shares of Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after buying an additional 664 shares during the last quarter. Crowley Wealth Management Inc. purchased a new stake in shares of Moderna in the fourth quarter worth approximately $41,000. Finally, MassMutual Private Wealth & Trust FSB lifted its stake in shares of Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after acquiring an additional 389 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Trading Down 3.1 %

Shares of MRNA opened at $31.12 on Friday. The firm has a market cap of $12.03 billion, a PE ratio of -3.35 and a beta of 1.86. Moderna, Inc. has a 12 month low of $29.25 and a 12 month high of $170.47. The stock has a fifty day moving average price of $34.72 and a 200-day moving average price of $44.62.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Bank of America cut their price objective on Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research report on Tuesday, February 11th. Evercore ISI set a $50.00 price objective on shares of Moderna in a report on Friday, February 14th. UBS Group dropped their target price on shares of Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a research note on Wednesday, February 19th. Barclays downgraded shares of Moderna from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $111.00 to $45.00 in a research note on Tuesday, February 18th. Finally, Morgan Stanley reduced their price objective on Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 15th. Four analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $59.00.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.